Expression of protein-tyrosine phosphatases in acute myeloid leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression

Cell Communication and Signaling

Volumn 10, Issue , 2012, Pages

  Arora, Deepika ^a   Köthe, Susanne ^a   Van Den Eijnden, Monique ^b   Van Huijsduijnen, Rob Hooft ^b   Heidel, Florian ^c   Fischer, Thomas ^c   Scholl, Sebastian ^a   Tölle, Benjamin ^a   Böhmer, Sylvia Annette ^a   Lennartsson, Johan ^d   Isken, Fabienne ^e   Müller Tidow, Carsten ^e   Böhmer, Frank D ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b MERCK SERONO S A   (Switzerland)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Dual specificity phosphatases (DUSP); DUSP6; ERK signaling; Fms like tyrosine kinase (FLT3) with internal tandem duplication (ITD); mRNA expression; Protein tyrosine phosphatases

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE;

ACP1 GENE; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; DUSP1 GENE; DUSP10 GENE; DUSP6 GENE; ENZYME ACTIVATION; ENZYME ACTIVITY; FLT3 ITD GENE; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PTEN GENE; PTP GENE; PTP4A1 GENE; PTP4A2 GENE; PTPN2 GENE; PTPN22 GENE; PTPN6 GENE; PTPRC GENE; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84865258885     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-10-19     Document Type: Article

References (47)

1. Protein-tyrosine phosphatases and cancer. stman A, Hellberg C, Böhmer FD, Nat Rev Cancer 2006 6 307 320 10.1038/nrc1837 16557282
2. Inside the human cancer tyrosine phosphatome. Julien SG, Dube N, Hardy S, Tremblay ML, Nat Rev Cancer 2011 11 35 49 10.1038/nrc2980 21179176
3. The role of Shp2 (PTPN11) in cancer. Mohi MG, Neel BG, Curr Opin Genet Dev 2007 17 23 30 10.1016/j.gde.2006.12.011 17227708 (Pubitemid 46131442)
4. Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis. Berman-Golan D, Granot-Attas S, Elson A, Cancer Metastasis Rev 2008 27 193 203 10.1007/s10555-008-9124-0 18231724
5. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al. Blood 2010 115 453 474 10.1182/blood-2009-07-235358 19880497
6. Genetics of myeloid malignancies: pathogenetic and clinical implications. Fröhling S, Scholl C, Gilliland DG, Levine RL, J Clin Oncol 2005 23 6285 6295 10.1200/JCO.2005.05.010 16155011 (Pubitemid 46218838)
7. Signal transduction of oncogenic Flt3. Choudhary C, Müller-Tidow C, Berdel WE, Serve H, Int J Hematol 2005 82 93 99 10.1532/IJH97.05090 16146838 (Pubitemid 41233166)
8. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Schmidt-Arras DE, Böhmer A, Markova B, Choudhary C, Serve H, Böhmer FD, Mol Cell Biol 2005 25 3690 3703 10.1128/MCB.25.9.3690-3703.2005 15831474 (Pubitemid 40559575)
9. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Heiss E, Masson K, Sundberg C, Pedersen M, Sun J, Bengtsson S, Rönnstrand L, Blood 2006 108 1542 1550 10.1182/blood-2005-07-008896 16684964 (Pubitemid 44316119)
10. Role of SHP2 for FLT3-dependent proliferation and transformation in 32D cells. Müller JP, Schönherr C, Markova B, Bauer R, Stocking C, Böhmer FD, Leukemia 2008 22 1945 1948 10.1038/leu.2008.73 18368066
11. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. Arora D, Stopp S, Böhmer SA, Schons J, Godfrey R, Masson K, Razumovskaya E, Rönnstrand L, Tänzer S, Bauer R, et al. J Biol Chem 2011 286 10918 10929 10.1074/jbc.M110.205021 21262971
12. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K, et al. PLoS One 2011 6 19798 10.1371/journal.pone.0019798 21589872
13. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R, Döhner H, Pollack JR, N Engl J Med 2004 350 1605 1616 10.1056/NEJMoa031046 15084693 (Pubitemid 38501163)
14. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Lowenberg B, Delwel R, Valk PJ, Haematologica 2009 94 131 134 10.3324/haematol.13299 18838472
15. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Döhner K, Dugas M, Klein HU, Döhner H, Ehninger G, Haferlach T, Leukemia 2011 24 1216 1220
16. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. Marcucci G, Haferlach T, Döhner H, J Clin Oncol 2011 29 475 486 10.1200/JCO.2010.30.2554 21220609
17. FLT3/ITD mutation signaling includes suppression of SHP-1. Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D, J Biol Chem 2005 280 5361 5369 15574429 (Pubitemid 40280010)
18. Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through a systematic genomics approach. Schmidt F, van den Eijnden M, Gobert RP, Saborio G, Carboni S, Alliod C, Pouly S, Staugaitis SM, Dutta R, Trapp B, Hooft V, Huijsduijnen R, PLoS One 2012 22363802
19. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, Boschert U, Arkinstall S, Science 1998 280 1262 1265 10.1126/science.280.5367. 1262 9596579 (Pubitemid 28269620)
20. Diverse physiological functions for dual-specificity MAP kinase phosphatases. Dickinson RJ, Keyse SM, J Cell Sci 2006 119 4607 4615 10.1242/jcs.03266 17093265 (Pubitemid 44964257)
21. Protein tyrosine phosphatases in the human genome. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T, Cell 2004 117 699 711 10.1016/j.cell.2004.05.018 15186772 (Pubitemid 38748887)
22. Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. Jurek A, Amagasaki K, Gembarska A, Heldin CH, Lennartsson J, J Biol Chem 2009 284 4626 4634 19106095
23. Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. Pulido R, Hooft van Huijsduijnen R, FEBS J 2008 275 848 866 10.1111/j.1742-4658.2008.06250.x 18298792 (Pubitemid 351230203)
24. Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester. Nunes-Xavier CE, Tarrega C, Cejudo-Marin R, Frijhoff J, Sandin A, stman A, Pulido R, J Biol Chem 2010 285 26417 26430 10.1074/jbc.M110.121830 20554528
25. Reversible phosphorylation in haematological malignancies: potential role for protein tyrosine phosphatases in treatment? Ruela-de-Sousa RR, Queiroz KC, Peppelenbosch MP, Fuhler GM, Biochim Biophys Acta 2010 1806 287 303 20659529
26. Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells. Arimura Y, Yagi J, Sci Signal 2010 3 s1 10.1126/scisignal.2000966 20807954
27. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ. Godfrey R, Arora D, Bauer R, Stopp S, Müller JP, Heinrich T, Böhmer SA, Dagnell M, Schnetzke U, Scholl S, et al. Blood 2012 119 4499 4511 10.1182/blood-2011-02-336446 22438257
28. Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Croonquist PA, Linden MA, Zhao F, Van Ness BG, Blood 2003 102 2581 2592 10.1182/blood-2003-04-1227 12791645 (Pubitemid 37193599)
29. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D, Blood 2005 105 1759 1767 10.1182/blood-2004-05-2006 15498859 (Pubitemid 40223700)
30. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. Xu S, Furukawa T, Kanai N, Sunamura M, Horii A, J Hum Genet 2005 50 159 167 10.1007/s10038-005-0235-y 15824892 (Pubitemid 40685330)
31. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A, Am J Pathol 2003 162 1807 1815 10.1016/S0002-9440(10)64315-5 12759238 (Pubitemid 36613039)
32. Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Furukawa T, Yatsuoka T, Youssef EM, Abe T, Yokoyama T, Fukushige S, Soeda E, Hoshi M, Hayashi Y, Sunamura M, et al. Cytogenet Cell Genet 1998 82 156 159 10.1159/000015091 9858808 (Pubitemid 29002456)
33. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Wong VC, Chen H, Ko JM, Chan KW, Chan YP, Law S, Chua D, Kwong DL, Lung HL, Srivastava G, et al. Int J Cancer 2012 130 83 95 10.1002/ijc.25970 21387288
34. A five-gene signature and clinical outcome in non-small-cell lung cancer. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al. N Engl J Med 2007 356 11 20 10.1056/NEJMoa060096 17202451 (Pubitemid 46041749)
35. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Messina S, Frati L, Leonetti C, Zuchegna C, Di Zazzo E, Calogero A, Porcellini A, Oncogene 2011 30 3813 3820 10.1038/onc.2011.99 21499306
36. Dual specificity phosphatase 6 (DUSP6) as a predictor of invasiveness in papillary thyroid cancer. Lee JU, Huang S, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM, et al. Eur J Endocrinol 2012
37. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Marchetti S, Gimond C, Chambard JC, Touboul T, Roux D, Pouyssegur J, Pages G, Mol Cell Biol 2005 25 854 864 10.1128/MCB.25.2.854-864.2005 15632084 (Pubitemid 40096604)
38. Signalling ballet in space and time. Kholodenko BN, Hancock JF, Kolch W, Nat Rev Mol Cell Biol 2010 11 414 426 10.1038/nrm2901 20495582
39. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Marshall CJ, Cell 1995 80 179 185 10.1016/0092-8674(95)90401-8 7834738
40. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Santos SD, Verveer PJ, Bastiaens PI, Nat Cell Biol 2007 9 324 330 10.1038/ncb1543 17310240 (Pubitemid 46344612)
41. Molecular interpretation of ERK signal duration by immediate early gene products. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J, Nat Cell Biol 2002 4 556 564 12134156
42. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. Mahboobi S, Uecker A, Sellmer A, Cenac C, Hocher H, Pongratz H, Eichhorn E, Hufsky H, Trumpler A, Sicker M, et al. J Med Chem 2006 49 3101 3115 10.1021/jm058033i 16722630 (Pubitemid 43830510)
43. Prognostically useful gene-expression profiles in acute myeloid leukemia. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R, N Engl J Med 2004 350 1617 1628 10.1056/NEJMoa040465 15084694 (Pubitemid 38528701)
44. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model. Agrawal-Singh S, Koschmieder S, Gelsing S, Stocking C, Stehling M, Thiede C, Thoennissen NH, Kohler G, Valk PJ, Delwel R, et al. Blood 2010 115 4507 4516 10.1182/blood-2009-03-210070 20215640
45. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on "substrate-trapping" mutants. Wälchli S, Curchod ML, Gobert RP, Arkinstall S, Hooft van Huijsduijnen R, J Biol Chem 2000 275 9792 9796 10.1074/jbc.275.13.9792 10734133 (Pubitemid 30185214)
46. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Weber K, Bartsch U, Stocking C, Fehse B, Mol Ther 2008 16 698 706 10.1038/mt.2008.6 18362927 (Pubitemid 351426171)
47. Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Schmidt-Arras D, Böhmer SA, Koch S, Muller JP, Blei L, Cornils H, Bauer R, Korasikha S, Thiede C, Böhmer FD, Blood 2009 113 3568 3576 10.1182/blood-2007-10-121426 19204327